当前位置: 首页 >> 检索结果
921. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.
作者: Hari S Conjeevaram.;Michael W Fried.;Lennox J Jeffers.;Norah A Terrault.;Thelma E Wiley-Lucas.;Nezam Afdhal.;Robert S Brown.;Steven H Belle.;Jay H Hoofnagle.;David E Kleiner.;Charles D Howell.; .
来源: Gastroenterology. 2006年131卷2期470-7页
Compared with Caucasian Americans (CA), African Americans (AA) with chronic hepatitis C are less likely to respond to interferon-based antiviral therapy.
922. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.
作者: José M Sánchez-Tapias.;Moisés Diago.;Pedro Escartín.;Jaime Enríquez.;Manuel Romero-Gómez.;Rafael Bárcena.;Javier Crespo.;Raúl Andrade.;Eva Martínez-Bauer.;Ramón Pérez.;Milagros Testillano.;Ramón Planas.;Ricard Solá.;Manuel García-Bengoechea.;Javier Garcia-Samaniego.;Miguel Muñoz-Sánchez.;Ricardo Moreno-Otero.; .
来源: Gastroenterology. 2006年131卷2期451-60页
Patients with chronic hepatitis C who do not respond rapidly to therapy have a low chance of developing a sustained virologic response (SVR) when treated for 48 weeks. This study investigated whether treatment for 72 weeks increases the rate of SVR in patients with detectable hepatitis C virus (HCV)-RNA levels at week 4 of treatment.
923. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
作者: Morris Sherman.;Cihan Yurdaydin.;Jose Sollano.;Marcelo Silva.;Yun-Fan Liaw.;Janusz Cianciara.;Anna Boron-Kaczmarska.;Paul Martin.;Zachary Goodman.;Richard Colonno.;Anne Cross.;Gail Denisky.;Bruce Kreter.;Robert Hindes.; .
来源: Gastroenterology. 2006年130卷7期2039-49页
Lamivudine treatment is associated with frequent development of resistant hepatitis B virus (HBV) and loss of treatment benefit. In preclinical and phase II studies, entecavir demonstrated potent antiviral activity against lamivudine-resistant HBV.
927. Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding: a randomized trial.
作者: J Michael Henderson.;Thomas D Boyer.;Michael H Kutner.;John R Galloway.;Layton F Rikkers.;Lennox J Jeffers.;Kareem Abu-Elmagd.;Jason Connor.; .
来源: Gastroenterology. 2006年130卷6期1643-51页
Variceal bleeding refractory to medical treatment with beta-blockers and endoscopic therapy can be managed by variceal decompression with either surgical shunts or transjugular intrahepatic portal systemic shunts (TIPS). This prospective randomized trial tested the hypothesis that patients receiving distal splenorenal shunts (DSRS) would have significantly lower rebleeding and encephalopathy rates than TIPS in management of refractory variceal bleeding.
928. Hepatopulmonary syndrome in patients with chronic liver disease: role of pulse oximetry.
作者: Peter Deibert.;Hans-Peter Allgaier.;Stefanie Loesch.;Claudia Müller.;Manfred Olschewski.;Hinrich Hamm.;Klaus-Peter Maier.;Hubert Erich Blum.
来源: BMC Gastroenterol. 2006年6卷15页
Hepatopulmonary syndrome (HPS) is a rare complication of liver diseases of different etiologies and may indicate a poor prognosis. Therefore, a simple non-invasive screening method to detect HPS would be highly desirable. In this study pulse oximetry was evaluated to identify patients with HPS.
929. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
作者: Gloria Taliani.;Giulia Gemignani.;Carlo Ferrari.;Antonio Aceti.;Dario Bartolozzi.;Pier Luigi Blanc.;Marco Capanni.;Francesco Esperti.;Paolo Forte.;Vincenzo Guadagnino.;Terenzio Mari.;Nicoletta Marino.;Stefano Milani.;Caterina Pasquazzi.;Floriano Rosina.;Danilo Tacconi.;Mario Toti.;Anna Linda Zignego.;Luca Messerini.;Tommaso Stroffolini.; .
来源: Gastroenterology. 2006年130卷4期1098-106页
Inadequate data are available about retreatment of nonresponders to interferon (IFN) and ribavirin. Thus, this study evaluated the efficacy and tolerability of a 48-week therapy with pegylated IFN-alpha-2b plus high-dose ribavirin in patients who have failed to respond to the combination. Treatment up to 48 weeks also in patients who have failed to clear hepatitis C virus (HCV) RNA by week 24 was also evaluated.
930. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
作者: Thomas Berg.;Michael von Wagner.;Samer Nasser.;Christoph Sarrazin.;Tobias Heintges.;Tilman Gerlach.;Peter Buggisch.;Tobias Goeser.;Jens Rasenack.;Gerd R Pape.;Wolfgang E Schmidt.;Birgit Kallinowski.;Hartwig Klinker.;Ulrich Spengler.;Peter Martus.;Ulrich Alshuth.;Stefan Zeuzem.
来源: Gastroenterology. 2006年130卷4期1086-97页
The treatment of patients infected with hepatitis C virus (HCV) type 1 remains a challenge necessitating innovative strategies to improve treatment outcome. The extension of treatment duration beyond 48 weeks is one possible strategy to address this problem.
931. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.
作者: Marc Lémann.;Jean-Yves Mary.;Bernard Duclos.;Michel Veyrac.;Jean-Louis Dupas.;Jean Charles Delchier.;David Laharie.;Jacques Moreau.;Guillaume Cadiot.;Laurence Picon.;Arnaud Bourreille.;Iradj Sobahni.;Jean-Frederic Colombel.; .
来源: Gastroenterology. 2006年130卷4期1054-61页
The aim of this study was to evaluate the usefulness of short-term infliximab combined with azathioprine (AZA) or 6-mercaptopurine (6-MP) in steroid-dependent Crohn's disease patients.
932. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia.
作者: Giuseppe Chiarioni.;William E Whitehead.;Vincenzo Pezza.;Antonio Morelli.;Gabrio Bassotti.
来源: Gastroenterology. 2006年130卷3期657-64页
Uncontrolled trials suggest biofeedback is an effective treatment for pelvic floor dyssynergia (PFD), a type of constipation defined by paradoxical contraction, or inability to relax, pelvic floor muscles during defecation. The aim was to compare biofeedback to laxatives plus education.
933. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.
作者: Sanaa M Kamal.;Amr E Fouly.;Refaat R Kamel.;Bridgette Hockenjos.;Ahmed Al Tawil.;Khalifa E Khalifa.;Qi He.;Margaret J Koziel.;Khairy M El Naggar.;Jens Rasenack.;Nezam H Afdhal.
来源: Gastroenterology. 2006年130卷3期632-8页
Pegylated interferon therapy has not been adequately evaluated in acute hepatitis C virus (HCV) infection. This randomized trial assessed the efficacy, safety, and timing of pegylated interferon alfa-2b for treatment of acute hepatitis C.
935. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
作者: Stephen B Hanauer.;William J Sandborn.;Paul Rutgeerts.;Richard N Fedorak.;Milan Lukas.;Donald MacIntosh.;Remo Panaccione.;Douglas Wolf.;Paul Pollack.
来源: Gastroenterology. 2006年130卷2期323-33; quiz 591页
Tumor necrosis factor blockade has been shown to be an effective treatment strategy in Crohn's disease (CD). Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor (TNF). A randomized, double-blind, placebo-controlled, dose-ranging trial was performed to evaluate the efficacy of adalimumab induction therapy in patients with CD.
936. Lifestyle as a predictor for colonic neoplasia in asymptomatic individuals.
Lifestyle is a well-established risk factor for colorectal cancer (CRC) and is also found to be associated with occurrence of adenomas. In the present study we evaluated risk factors for both low-risk adenomas and advanced neoplasia in asymptomatic individuals using a single-paged questionnaire. Aiming to see if the questionnaire was a useful tool in picking up high-risk individuals.
937. A comparison of oral omeprazole and intravenous cimetidine in reducing complications of duodenal peptic ulcer.
作者: Manouchehr Khoshbaten.;Ebrahim Fattahi.;Nosratollah Naderi.;Farzaneh Khaleghian.;Mohammadreza Rezailashkajani.
来源: BMC Gastroenterol. 2006年6卷2页
Gastrointestinal bleeding is a common problem and its most common etiology is peptic ulcer disease. Ulcer rebleeding is considered a perilous complication for patients. To reduce the rate of rebleeding and to fasten the improvement of patients' general conditions, most emergency departments in Iran use H2-blockers before endoscopic procedures (i.e. intravenous omeprazole is not available in Iran). The aim of this study was to compare therapeutic effects of oral omeprazole and intravenous cimetidine on reducing rebleeding rates, duration of hospitalization, and the need for blood transfusion in duodenal ulcer patients.
938. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension.
作者: Steeve Provencher.;Philippe Herve.;Xavier Jais.;Didier Lebrec.;Marc Humbert.;Gerald Simonneau.;Olivier Sitbon.
来源: Gastroenterology. 2006年130卷1期120-6页
It has been suggested that beta-blockers might be harmful in pulmonary arterial hypertension. However, no study has evaluated the effect of beta-blockers in these patients. The aim of this study was to investigate the effect of beta-blockers on exercise capacity and pulmonary hemodynamics in patients with portopulmonary hypertension receiving beta-blockers for the prophylaxis of variceal bleeding.
939. Cholecystectomy or gallbladder in situ after endoscopic sphincterotomy and bile duct stone removal in Chinese patients.
作者: James Y W Lau.;Chon-Kar Leow.;Terence M K Fung.;Bing-Yee Suen.;Ly-Mee Yu.;Paul B S Lai.;Yuk-Hoi Lam.;Enders K W Ng.;Wan Yee Lau.;Sydney S C Chung.;Joseph J Y Sung.
来源: Gastroenterology. 2006年130卷1期96-103页
In patients with stones in their bile ducts and gallbladders, cholecystectomy is generally recommended after endoscopic sphincterotomy and clearance of bile duct stones. However, only approximately 10% of patients with gallbladders left in situ will return with further biliary complications. Expectant management is alternately advocated. In this study, we compared the treatment strategies of laparoscopic cholecystectomy and gallbladders left in situ.
940. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
作者: Susanne Fries.;Tilo Grosser.;Thomas S Price.;John A Lawson.;Shiv Kapoor.;Susan DeMarco.;Mathew T Pletcher.;Tim Wiltshire.;Garret A FitzGerald.
来源: Gastroenterology. 2006年130卷1期55-64页
Variability in response to drugs may influence both efficacy and safety. Cyclooxygenase (COX)-2 inhibitors pose a cardiovascular risk by potentially increasing the likelihood of thrombosis, hypertension, and atherogenesis. Differences between individuals in the response to COX-2 inhibitors would be expected to influence their susceptibility to cardiovascular complications. We examined the variability in degree and selectivity of COX-2 inhibition in humans in response to celecoxib and rofecoxib.
|